Thus, the three-drug combination of sirolimus, venetoclax, and S63845 is well tolerated at effective dosages in vivo and shows activity against human as well as zebrafish NF1/PTEN-deficient melanoma cells, providing preclinical evidence justifying an early-stage clinical trial in patients with melanomas of this high-risk genomic subtype. Here, NF1 is linked to melanoma.